

15 April 2025

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Appointment of Professor Andrew Way AM as a Non-Executive Director

Melbourne, Victoria – Alcidion Group Limited (ASX: ALC) (**Alcidion** or **Company**) is pleased to announce the appointment of Professor Andrew Way AM as a Non-Executive Director, effective today, as part of Alcidion's active board succession program.

Andrew will fill the board position of Victoria Weekes who will be stepping down mid-year enabling an important transition period to onboard Andrew, and to finalise a reorganisation of committees. Victoria has served on the Alcidion Board for more than three years where she has enhanced the governance framework aligned with the maturing of Alcidion's operations. Victoria's leadership on the Board and in her capacity as the Chair of the Audit and Risk Committee has had significant impact as the size and complexity of Alcidion's customers has evolved applying her specific knowledge in public health and experience with some of Australia's largest businesses.

Alcidion's Chair, Ms Rebecca Wilson said: *"On behalf of the Board I'd like to thank Victoria for her contribution over the last 3 years where she effectively used her extensive Board experience with large, mature companies, to positively influence Alcidion's approach to risk and governance in an important period of growth. Victoria's deep business experience combined with her specific knowledge of Australia's public healthcare landscape through her experience on the Board of the Sydney Local Health District were influential during her tenure."*

Professor Way brings a wealth of experience to the Board of Alcidion, having served as the Chief Executive of Alfred Health from 2009 to 2024 as well as having held several senior positions in the England National Health Service (NHS). Andrew also led the development of Monash Partners, Victoria's first Academic Health Science Centre and was appointed as an Adjunct Clinical Professor in the School of Public Health and Preventative Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University in 2015. In addition to his senior leadership roles, Professor Way holds several non-executive and advisory roles both in Australia and internationally including Chair of the Department of Health's HSV (Health Services Victoria) Board.

His expertise in quality and safety in patient care, the development of academic medical organisations, management of complex healthcare systems and using IT as a clinical enabler will contribute significantly to Alcidion. He also brings strong customer insights to the Board with Alfred Health being a long-standing customer of Alcidion.

Alcidion's Chair, Ms Rebecca Wilson, said: *"I'm very pleased to welcome Andrew to the Board. He brings deep sector knowledge and skills that are strongly aligned to Alcidion's core purpose in supporting the healthcare industry and will be a great asset to the Company as we continue to execute on our strategic plan."*

"Andrew is the second new appointment, following that of Will Smart last year, of a director with deep international operational healthcare experience that comes at a time when we embark on the next phase of scaling the Company and expanding our customer base."

ENDS

Authorised for ASX release by the Board of Alcidion Group Limited.

For further information, please contact:

Investor Relations

investor@alcidion.com

About Alcidion

Alcidion Group Limited has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2025